OC-459
OC-459 is in phase II clinical trials for the treatment of allergic rhinitis, asthma, allergic conjunctivitis, atopic dermatitis.
The compound was co-developed by Oxagen Ltd and Atopix Therapeutics.
General Information
Update Date：2015-10-12
- Drug Name：
- OC-459
- Research Code：
- OC-459; OC-000459
- Trade Name：
- MOA：
- CRTH2 receptor antagonist
- Indication：
- Allergic rhinitis (AR); Asthma; Allergic conjunctivitis; Atopic dermatitis
- Status：
- Phase II (Active)
- Company：
- Oxagen (Originator), Atopix Therapeutics (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-12
|
Molecular Weight | 348.37 | ||||||||||||
| Formula | C21H17FN2O2 | |||||||||||||
| CAS No. | 851723-84-7 (OC000459); | |||||||||||||
| Chemical Name | 1H-Indole-1-acetic acid, 5-fluoro-2-methyl-3-(2-quinolinylmethyl)- | |||||||||||||
| OC000459 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||